

Capstone Therapeutics Corp.  
Form S-8 POS  
March 21, 2019

As filed with the United States Securities and Exchange Commission on March 21, 2019

Registration No. 333-196828

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

**Post-Effective Amendment No. 1 to**

**Form S-8 Registration Statement**

**UNDER THE SECURITIES ACT OF 1933**

---

**CAPSTONE THERAPEUTICS CORP.**

(Exact name of registrant as specified in its charter)

|  |  |
|--|--|
| <b>Delaware</b><br>(State or other jurisdiction of<br>incorporation or organization) | <b>86-0585310</b><br>(I.R.S. Employer<br>Identification No.) |
|--|--|

1275 W. Washington Street, Suite 104  
Tempe, Arizona

85281

(Address of Principal Executive Offices) (Zip Code)

\_\_\_\_\_

**Capstone Therapeutics Corp. 2005 Equity Incentive Plan**

(Full title of the plan)

\_\_\_\_\_

Les M. Taeger

*Copy to:*

Senior Vice President, Chief Financial Officer, Jacque Westling

Capstone Therapeutics Corp.

Quarles & Brady LLP

1275 W. Washington Street, Suite 104

Renaissance One, Two North Central Avenue

Tempe, AZ 85281

Phoenix, AZ 85004

(Name and address of agent for service)

(602)-286-5520

(Telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer

Non-accelerated filer  Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. "

## **DEREGISTRATION OF SECURITIES**

Capstone Therapeutics Corp. (the “Registrant”) is filing this Post-Effective Amendment No. 1 (this “Post-Effective Amendment”) to the Registration Statement on Form S-8, No. 333-196828 (the “Registration Statement”) to terminate the effectiveness of the Registration Statement and to remove from registration all securities that remain unsold under the Capstone Therapeutics Corp. 2005 Equity Incentive Plan.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tempe, State of Arizona, on March 21, 2019.

**CAPSTONE  
THERAPEUTICS  
CORP.**

By: /s/ Les M. Taeger  
Les M. Taeger  
*Senior Vice  
President and  
Chief Financial  
Officer*

No other person is required to sign these Post-Effective Amendments on behalf of the Registrant in reliance upon Section 478 of the Securities Act of 1933, as amended.